Skip to main content
SpringerLink
Log in

Clinical development of trastuzumab in Breast Cancer

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

The HER-2/neu protein is thought to be a unique and useful target for antibody therapy of cancers overexpressing the HER-2/neu gene. The recombinant humanized arti-HER-2 monoclonal antibody, trastuzumab (HerceptinTM) is now available for clinical use in the U.S.A. It is also expected to be available in Japan in the near future. In this paper, the details of this novel biologic agent are reviewed in conjunction with a phase I study performed in Japan.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Yarden Y, Ullrich A: Growth factor receptor tyrosine kinases.Annu Rev Biochem 57:443–478, 1988.

    Article  PubMed  CAS  Google Scholar 

  2. Coussens L, Yang-Feng TL, Iiao Y-C,et al: Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene.Science 230:1132–1139, 1985.

    Article  PubMed  CAS  Google Scholar 

  3. Yamamoto T, Ikawa S, Akiyama T,et al: Similarity of protein encoded by human c-erbB-2 gene to epidermal growth factor receptor.Nature 319:230–234, 1986

    Article  PubMed  CAS  Google Scholar 

  4. King CR, Kraus MH, Aronson SA Amplification of a novel v-erbB-related gene in a human mammary carcinoma.Science 229:974–976, 1985.

    Article  PubMed  CAS  Google Scholar 

  5. Slamon DJ, Godolphin W, Jones LA,et al: Studies of th.HER-2/neu proto-oncogene in human breast and ovarian cancer.Science 244:707–712, 1989.

    Article  PubMed  CAS  Google Scholar 

  6. De Porer CR, Van Daele S, Van De Vijver MJ,et al: The expression of the neu oncogene in breast lesions and in normal fetal and adult human tissues.Histopathology 15:315–326, 1989.

    Google Scholar 

  7. Prss MF, Cerdon-Cardo C, Slamon DJ: Expression of th.HER-2/neu proto-oncogene in normal human adult and fetal tissues.Oncogene 5:953–962, 1990.

    Google Scholar 

  8. Drebin JA, Link VC, Stern DF,et al: Down modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies.Cell 41:695–706, 1985.

    Article  Google Scholar 

  9. Hudziak RM, Lewis GD, Winget M,et al: pl85HER2 monoclonal antibody has antiproliferative effects in vitro and sensitized human breast tumor cells to tumor necrosis factor.Mol Cell Biol 9:1165–1172, 1989.

    PubMed  CAS  Google Scholar 

  10. Hancock MC, Langton BC, Chan T,et al: A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumour cell lines.Cancer Res 51:4575–4580, 1991.

    PubMed  CAS  Google Scholar 

  11. Stancovski I, Hurwitz E, Leitner O,et al: Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB-2 receptor on tumor growth.Proc Natl Acad Sci USA 88:8691–8695, 1991.

    Article  PubMed  CAS  Google Scholar 

  12. Tagliabue E, Centis F, Campiglio M,et al: Selection of monoclonal antibodies which induce internalization and phosphorylation of pl85HER2 and growth inhibition of cells wit.HER2/neu gene amplification. Int J Cancer 47:933–937, 1991.

    Article  PubMed  CAS  Google Scholar 

  13. Harwerth I-M, Wels W, Marte BM,et al: Monoclonal antibodies against the extracellular domain of th.erbB-2 receptor function as partial ligand agonists.J Biol Chem 267:15160–15167, 1992.

    PubMed  CAS  Google Scholar 

  14. Kasprzyk PG, Song SU, Di Fiore PP,et al: Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2monoclonal antibodies.Cancer Res 52:2771–2776, 1992.

    PubMed  CAS  Google Scholar 

  15. Schroff RW, Foon KA, Beatty SM,et al: Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy.Cancer Res 45:879–885, 1985.

    PubMed  CAS  Google Scholar 

  16. Ohnish Y, Nakamura H, Yoshimura M,et al: Prolonged survival of mice with human gastric cancer treated with an anti-c-erbB-2 monoclonal antibody.Br J Cancer 71:969–973, 1995.

    Google Scholar 

  17. Shawler DL, Bartholomew RM, Smith LM,et al: Human immune response to multiple injection of murine monoclonal IgG.J Immunol 135:1530–1535, 1985.

    PubMed  CAS  Google Scholar 

  18. Carter P, Presta L, Gorman CM,et al: Humanization of an anti-pl85HEB2 antibody for human cancer therapy.Proc Natl Acad Sci USA 89:4285–4289, 1992.

    Article  PubMed  CAS  Google Scholar 

  19. Tokuda Y, Ohnish Y, Shimamura K,et al: In vitro an.in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product.Br J Cancer 73:1362–1365, 1996.

    PubMed  CAS  Google Scholar 

  20. Cobleigh MA, Vogel CL, Tripathy D,et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who hav.HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.J Clin Oncol 17:2639–2648, 1999.

    PubMed  CAS  Google Scholar 

  21. Tokuda Y, Watanabe T, Omuro Y,et al: Dose escalation and pharmacokinetic study of a humanised anti-HER2 monoclonal antibody in patients wit.HER2/neu-over-expressing metastatic breast cancer.Br J Cancer 81:1419–1425, 1999.

    Article  PubMed  CAS  Google Scholar 

  22. Vogel C, Cobleigh M, Tripathy D,et al: First-line, non-hormonal, treatment of women withHER2 over-expressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody).Proc Am Soc Clin Oncol 19:71a, 2000 (abstr 275).

    Google Scholar 

  23. Pegram M, Hsu S, Lewis G,et al: Inhibitory effects of combinations o.HER-2/neu antibody and chemother-apeutic agents used for treatment of human breast cancers.Oncogene 18:2241–2251, 1999.

    Article  PubMed  CAS  Google Scholar 

  24. Slamon D, Leyland-Jones B, Shak S,et al: Addition of HerceptinTM (humanized anti-HER2 antibody) to first line chemotherapy forHER2 overexpressing metastatic breast cancer(HER2 + /MBC) markedly increase anticancer activity: a randomized multinational controlled phase III trial.Proc Am Soc Clin Oncol 17:98a, 1998 (abstr 377).

    Google Scholar 

  25. Seidman A, Fornier M, Esteva F,et al: Final report: weekly (W) Herceptin and Taxol (T) for metastatic breast cancer (MBC): analysis of efficacy byHER2 immunophenotype (immunohistochemistry (IHC) and gene amplification (fluorescent in-situ hybridization (FISH)).Proc Am Soc Clin Oncol 19:83a, 2000 (abstr 319).

    Google Scholar 

  26. Burstein H, Kuter I, Richardson P,et al: Herceptin and vinorelbine forHER2-positive metastatic breast cancer: a phase II study.Proc Am Soc Clin Oncol 19:102a, 2000 (abstr 392).

    Google Scholar 

  27. Mass RD, Sanders C, Charlene K,et al: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridization (FISH) in the Herceptin pivotal trials.Proc Am Soc Clin Oncol 19:75a, 2000 (abstr 291).

    Google Scholar 

  28. Buehler H, Bangemann N, Evers K,et al: EffectiveHER-2/neu diagnosis in breast cancer by a combination of immunohistochemistry and FISH.Proc Am Soc Clin Oncol 19:76a, 2000 (abstr 294).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Tokai University School of Medicine, Japan

    Yutaka Tokuda, Masatoshi Ohta, Yasuhiro Suzuki, Mitsuhiro Kubota & Tomoo Tajima

Authors
  1. Yutaka Tokuda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Masatoshi Ohta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasuhiro Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mitsuhiro Kubota
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomoo Tajima
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Tokuda, Y., Ohta, M., Suzuki, Y. et al. Clinical development of trastuzumab in Breast Cancer. Breast Cancer 8, 93–97 (2001). https://doi.org/10.1007/BF02967486

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967486

Key words

Search

Navigation